

Understanding and Discussing the Implications of FDA's Sentinel Initiative

Grand Hyatt Washington
1000 H Street NW • Washington, DC
October 25, 2011

Attendees

Nayan Acharya
Senior Director, Office of Risk Management and
Pharmacoepidemiology, Eli Lilly and Co.

Raymond Bain
Vice President, Biostatistics and Research Decision
Sciences, Merck and Co.

Robert Ball
Director, Office of Biostatistics and Epidemiology,
Center for Biologics Evaluation and Research (CBER),
U.S. Food and Drug Administration

Dorothee B. Bartels
Corporate Vice President/Head of Global
Epidemiology, Boehringer Ingelheim GmbH and
Associate Professor, Hannover Medical School

Donald Beers
Associate Chief Counsel for Drugs, U.S. Food and Drug
Administration

Carmen Bozic
Senior Vice President and Global Head, Safety and
Benefit-Risk Management, Biogen Idec

Stanley Bukofzer
Vice President, Medical and Scientific Affairs, Astellas
Pharma US Inc.

Patrizia Cavazzoni
Senior Vice President for Worldwide Safety Strategy,
Pfizer Inc.

Henry Che
Associate Director, Safety Information Management,
Product Safety and Pharmacovigilance, Astellas
Pharma Global Development

Sally Cluchey
Senior Research Associate, Engelberg Center for Health
Care Reform, The Brookings Institution

Christopher Corsico
Senior Vice President, Medicine and Regulatory Affairs,
Regional Medical Director, North America, Boehringer
Ingelheim Pharmaceuticals, Inc.

Milbhor D'Silva
Vice President Pharmacovigilance and Safety, Astellas
Pharma Global Development, Inc.

Rosanne Ferguson
Director of Network for Medtronic's Post Approval
Network, Medtronic, Inc.

Thomas P. Gross
Acting Director, Office of Surveillance and Biometrics,
Center for Devices and Radiological Health (CDRH),
U.S. Food and Drug Administration

Ken Hornbuckle
Senior Epidemiology Advisor, Office of Risk
Management and Pharmacoepidemiology, Global
Patient Safety Organization, Eli Lilly and Co.

Ralph Horwitz
Senior Vice President for Clinical Evaluation Sciences
and Senior Advisor to the Chairman of Research and
Development, GlaxoSmithKline

Janet Jenkins-Showalters
Director, FDA Liaison, Pharmaceutical Development
Regulatory, Hoffmann-La Roche/ Genentech

Juhaeri Juhaeri
Senior Director, Global Pharmacovigilance and
Epidemiology, Sanofi-Aventis

Erin Karnes
Research Associate, Engelberg Center for Health Care
Reform, The Brookings Institution

Larry Kocot
Deputy Director and Visiting Scholar, Engelberg Center
for Health Care Reform, The Brookings Institution

Elias Kouchakji
Executive Medical Director, Global Regulatory Affairs
and Safety, Amgen Inc.

Elliott Levy
Senior Vice-President, Global Pharmacovigilance and
Epidemiology, Bristol-Myers Squibb

Eddie E. Li
Vice President, Regulatory Affairs, Novo Nordisk Inc.

Mary Liu
Post-Doctoral Fellow, Pharmaceutical Development
Regulatory, Hoffman-La Roche/Genentech

David Martin
Acting Director, Division of Epidemiology, Office of
Biostatistics and Epidemiology, Center for Biologics
Evaluation and Research (CBER), U.S. Food and Drug
Administration

Mark McClellan
Director, Engelberg Center for Health Care Reform,
Senior Fellow, Economic Studies, and Leonard D.
Schaeffer Chair in Health Policy Studies, The Brookings
Institution

Qais A. Mekki
Vice President, Pharmacovigilance, Takeda Global
Research and Development Center, Inc.

Robert Meyer
Vice President, Global Regulatory Strategy, Policy and
Safety, Merck and Co.

Briggs Morrison
Senior Vice President, Worldwide Medical Excellence,
Pfizer Inc.

Garry Neil
Corporate Vice President, Corporate Office of Science
and Technology, Johnson & Johnson

Steve Niemcryk
Head, Global Surveillance and Pharmacoepidemiology,
Global Pharmacovigilance, Abbott Laboratories

John J. Orloff
Chief Medical Officer and Senior Vice President,
Novartis Pharmaceuticals

Sara Palmer
Senior Counsel, Research and Development, Legal
Operations, GlaxoSmithKline

Vaishali Patadia
Director and Head, Pharmacoepidemiology, Astellas
Pharma Global Development, Inc.

Richard Platt
Professor and Chair, Department of Population
Medicine at Harvard Medical School and the Harvard
Pilgrim Health Care Institute

Melissa Robb
Project Director for the Sentinel Initiative, Center for
Drug Evaluation and Research (CDER), U.S. Food and
Drug Administration

Patrick Ryan
Associate Director of Analytical Epidemiology, Johnson
& Johnson and Co-investigator, Observational Medical
Outcomes Partnership

Alfred Sandrock
Senior Vice President, Development, Biogen Idec

Jeffrey Secunda
Vice President, Technology & Regulatory Affairs,
AdvaMed

Rachel Sherman
Associate Director for Medical Policy, Center for Drug
Evaluation and Research (CDER), U.S. Food and Drug
Administration

David Smith
US Regulatory Law Lead, Pfizer Inc.

J. Michael Sprafka
Executive Director, Observational Research, Amgen
Inc.

Scott Terrillion
Vice President, Associate General Counsel, Boehringer
Ingelheim Pharmaceuticals, Inc.

Michelle Thompson
Senior Director, Regulatory Affairs, Novo Nordisk Inc.

Janet Woodcock
Director, Center for Drug Evaluation and Research
(CDER), U.S. Food and Drug Administration (FDA)